Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
31 Results for "
TDP-43
" in MedChemExpress (MCE) Product Catalog:
Products (31)
31 Results for "TDP-43" in MCE Product Catalog:
6
6 Publications Verification
Target:
Research Areas:
EN6 is a small-molecule in vivo autophagy activator that covalently targets cysteine 277 in the ATP6V1A subunit of the lysosomal v-ATPase. EN6-mediated modification of ATP6V1A uncouples v-ATPase from Rag, leading to inhibition of mTORC1 signalling, increased lysosomal acidification, and activation of autophagy. EN6 also scavenges TDP-43 aggregates (causative agents of frontotemporal dementia) in a lysosome-dependent manner .
1
1 Cited Publications
Cat. No.: HY-163574
CAS No.: 3033951-71-9
Target:
Research Areas:
TDP-43 ligand-1 is a specific ligand for TDP43, and its Ki value for binding to TDP-43 protein aggregates is 78 nM. TDP-43 ligand-1 can be used in the research of PET imaging probes for TDP-43 proteinopathies.
1
1 Cited Publications
Cat. No.: HY-W012985
CAS No.: 600-22-6
Target:
Research Areas:
Methyl pyruvate is a p53/p21 axis inhibitor, intrinsic apoptosis inhibitor, cytotoxic agent, ATP production enhancer, proteasome function restorer, TDP-43 localization normalizer, ATP-sensitive potassium (K +ATP) channel inhibitor, depolarizer, and insulin secretagogue .Methyl pyruvate turns off apoptotic pathways, induces cancer cell death, acts as a substrate for dimeric dihydrodiol dehydrogenase, enhances TCA cycle activity, rescues proteasome impairment and TDP-43 mislocalization, inhibits K +ATP channels independent of ATP, depolarizes pancreatic β-cell membranes, modulates insulin secretion, and enters pancreatic β-cell mitochondria via a specific transporter .Methyl pyruvate can be used for the research of lung adenocarcinoma, ovarian clear cell adenocarcinoma, breast adenocarcinoma, amyotrophic lateral sclerosis, and type II diabetes .
1
1 Cited Publications
Cat. No.: HY-17539
CAS No.: 1421919-75-6
Research Areas:
KPT-276 is an orally active and blood-brain barrier-penetrant selective XPO1/CRM1 inhibitor. KPT-276 blocks XPO1-mediated nuclear export function and promotes nuclear retention of various tumor suppressor proteins. KPT-276 induces apoptosis and G1 cell cycle arrest in tumor cells, and downregulates c-MYC, CDC25A, and BRD4. KPT-276 reduces immune cell proliferation through nuclear accumulation of cell cycle inhibitors, rescues TDP-43 cytoplasmic mislocalization, and restores axon growth and growth rate in mutant PFN1 motor neurons. KPT-276 maintains axonal cytoskeletal integrity and mitochondrial function, and inhibits tumor growth. KPT-276 can be used for research on glioblastoma, non-Hodgkin lymphoma, amyotrophic lateral sclerosis, multiple myeloma, and non-small cell lung cancer .
1
1
1 Cited Publications
Cat. No.: HY-P71788
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: TARDBP; TDP43; TAR DNA Binding Protein; TAR DNA Binding Protein, Isoform CRA_c; TDP-43; TAR DNA-Binding Protein-43; TAR DNA-Binding Protein 43; TDP43 Isoform F; ALS10
Species:
Human
Source:
E. coli
Cat. No.: HY-163575
CAS No.: 3033951-93-5
Synonyms: TDP-43-IN-2
Target:
Research Areas:
ACI-19626 (TDP-43-IN-2) is a TDP-43 aggregation inhibitor that can be used in the research of neurodegenerative diseases .
Cat. No.: HY-160115
CAS No.: 2902692-25-3
Target:
Research Areas:
TDP-43 degrader-1 (Compound example 7) is a TDP-43 degrader. TDP-43 degrader-1 reduces the aggregation of TDP-43-positive HuR stress granules in cells and promotes the relocalization of abnormally distributed TDP-43 in the cytoplasm to the nucleus. TDP-43 degrader-1 can be used in the study of amyotrophic lateral sclerosis and Alzheimer's disease .
Target:
Research Areas:
BSc5367 is a NEK1 kinase inhibitor with an IC50 of 11.5 nM. BSc5367 modulates the cell cycle, DNA repair, and microtubule dynamics, reduces YAP1 phosphorylation, induces DNA damage, and upregulates γH2A.X. BSc5367 drives TDP-43 nucleocytoplasmic translocation, inhibits NEK1-mediated ETS1 phosphorylation, increases ETS1 acetylation, sensitizes ccRCC cells to Sunitinib (HY-10255A), and mimics the phenotype of NEK1-mutant motor neurons. BSc5367 inhibits NEK1 in zebrafish models and causes expansion of renal tubule volume, affecting pronephros development. BSc5367 can be used in research related to polycystic kidney disease, renal cancer, and amyotrophic lateral sclerosis .
Target:
Research Areas:
rTRD01 is an orally active, specific TDP-43 binder that targets the RRM1 and RRM2 domains of TDP-43. rTRD01 partially disrupts the interaction between TDP-43 and c9orf72 repeat RNA, but does not affect the binding of TDP-43 to canonical binding sequences. rTRD01 exhibits significant neuroprotective effects in zebrafish models, improves motor function and protects against paraquat (a widely used herbicide)-induced neurodegeneration, with no teratogenicity at high concentrations. rTRD01 is not a general antioxidant and cannot counteract Rotenone (HY-B1756)-induced neuronal death. rTRD01 can be used to study amyotrophic lateral sclerosis and other TDP-43 proteinopathies .
Cat. No.: HY-179492
CAS No.: 3033951-64-0
Target:
Research Areas:
ACI-19278 is a TDP-43 PET tracer with an average Kd of 25 nM. ACI-19278 only binds to pathological TDP-43 aggregates and does not cross-react with Aβ, Tau, etc. [ 18F]ACI-19278 successfully visualized the TDP-43 pathology in the human brain through positron emission computed tomography. ACI-19278 can be used for in vivo diagnosis of TDP-43 protein lesions .
Target:
Research Areas:
TTBK1-IN-2 (compound 29) is a potent Tau-Tubulin kinase (TTBK1) inhibitor with IC50s of 0.24 and 4.22 µM, respectively. TTBK1-IN-2 reveals good brain penetration in vivo and is able to reduce TDP-43 phosphorylation not only in cell cultures but also in the spinal cord of transgenic TDP-43 mice .
Cat. No.: HY-172450
CAS No.: 1841140-38-2
Target:
Research Areas:
AIM4 is a TDP-43 aggregation inhibitor. AIM4 binds to the TDP-43 C-terminal amyloidogenic core and C-terminal fragments, antagonizing liquid-liquid phase separation, amyloid-like aggregation, and oligomer formation, while polarizing microglia toward an anti-inflammatory state. AIM4 can be used for research on amyotrophic lateral sclerosis .
Target:
Research Areas:
GDC-0134 (RG6000) is a modulator targeting dual leucine zipper kinase (DLK) that can cross the blood-brain barrier. By inhibiting the kinase activity of DLK, GDC-0134 blocks the activation of the downstream JNK signaling pathway, suppresses DLK-dependent retrograde signal transduction of axon-to-soma degeneration, and exerts neuroprotective activity. GDC-0134 reduces TDP-43 protein aggregation and decreases the degree of neuromuscular junction denervation in motor neurons. GDC-0134 can be used in the research of amyotrophic lateral sclerosis (ALS), Alzheimer's disease and other DLK-related neurodegenerative diseases .
Cat. No.: HY-17660
CAS No.: 959554-92-8
Target:
Research Areas:
G923-0271 is a TDP-43 protein inhibitor. G923-0271 can be used for the research of neurological disease, such as Alzheimer's Disease .
Cat. No.: HY-176381
CAS No.: 2250382-80-8
Research Areas:
BTK ligand 11-alcohol-PEG6-azido is a synthesized E3 ligase ligand-linker conjugate that can be used in the synthesis of PROTACs, such as TDP-43 degrader-1 (HY-122828) .
Cat. No.: HY-181846
CAS No.: 1065567-62-5
Target:
Research Areas:
nTRD22 is an RNA-binding allosteric modulator targeting TDP-43. nTRD22 binds to the N-terminal domain of TDP-43, thereby allosterically regulating the RNA-binding domain of TDP-43 and reducing its RNA-binding ability. nTRD22 decreases the TDP-43 protein level in primary motor neurons. nTRD22 alleviates motor dysfunction in amyotrophic lateral sclerosis models. nTRD22 is applicable to related research on amyotrophic lateral sclerosis .
Cat. No.: HY-RS23806
Target:
Research Areas:
Tardbp Rat Pre-designed siRNA Set A contains three designed siRNAs for Tardbp gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-172544
CAS No.: 2857982-34-2
Target:
Research Areas:
TTBK1/2-IN-3 (Compound 10) is a potent inhibitor of tau tubulin kinase 1 (TTBK1) and TTBK2, with IC50 values of 579 nM and 258 nM, respectively. TTBK1/2-IN-3 inhibits the phosphorylation of TDP-43. TTBK1/2-IN-3 reduces the expression of primary cilia on the surface of iPSCs .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
